No therapeutic product is ever completely risk free. Some risks may be known when a medicine is first entered on the market. However, some information only comes to light after more people use the products.
This webpage was developed to provide the public and healthcare professionals with easy access to important drug safety information. The webpage contains the most recent drug safety communications from SAHPRA as well as links for early communications and follow-up.
Alerts provide important information and recommendations about therapeutic products. When an alert is issued, it does not necessarily mean a product is considered unsafe.
Title | Version | SubVersion | Publish Date |
---|---|---|---|
Communication to Public - Summary of Medicines Safety Regulatory Decisions | V1 | 1.1 | 13-June-2022 |
A SIGNAL OF MYOCARDITIS / PERICARDITIS ASSOCIATED WITH PFIZER-BIONTECH’S COVID-19 VACCINE, COMIRNATY (BNT162B2) | V1 | 1.1 | 26-August-2021 |
SAHPRA Statement on Adverse Events Following Immunisation (AEFIs) with COVID 19 Vaccines | V1 | 1.1 | 20-August-2021 |
SAHPRA launches the Med Safety App for self-reporting of suspected Adverse Drug Reactions by the Public and Healthcare Professionals | V1 | 1.1 | 22-April-2021 |
To all stakeholders
Kindly note different email addresses that should be used for different vigilance submissions as stipulated below.
For submission of:
Please refrain from sending one document to all email addresses as this create duplication of reporting and misuse of resources.